Abstract: The invention relates to a method for characterising bone, the method comprising the steps of receiving (102) ultrasonic wave echo signals transmitted into a body, determining (104) a speed of sound in the body's non-bone biological tissue, locating (106) a first demarcation curve between non-bone biological tissue and bone in an image of the body constructed during said determining step, and determining (108) a speed of sound in bone. The steps of determining speed include constructing images from the signals, and a metric calculation indicative of a focus quality in the constructed images.

Abstract: The present invention relates to a process for preparing a polymer/biological entities alloy, comprising a step of mixing a polymer and biological entities that degrade it, during a heat treatment, said heat treatment being performed at a temperature T above room temperature and said biological entities being resistant to said temperature T, characterized in that said biological entities are chosen from enzymes that degrade said polymer and microorganisms that degrade said polymer.

Abstract: A radio frequency micro-electromechanical switch (generally referred to using the acronyms RF MEMS) is described. Also described is a method of producing such an RF MEMS switch.

Abstract: A device for medical analyses with cellular impedance signal processing comprises a memory (4) arranged to receive pulse data sets, each pulse data set comprising impedance value data that are associated each time with a time marker, these data together representing a curve of cellular impedance values that are measured as a cell passes through a polarized opening, a computer (6) arranged to process a pulse data set by determining a rotation value indicating whether the cell from which this pulse data set has been taken has undergone a rotation during its passage through the polarized opening, and a classifier (8) arranged to retrieve from the computer (6) a given pulse data set, and to use the resulting rotation value to classify the given pulse data set in a rotation pulse data set group (10) or a rotationless pulse data set group (12).

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: A method for producing an optoelectronic device having nitride-based microLEDs includes providing an assembly having at least one growth substrate and a nitride structure, where the nitride structure has a semipolar nitride layer that includes an active stack and crystallites extending from facets of the growth substrate with a crystalline orientation {111} to the first face of the semipolar nitride layer and providing an integrated control circuit featuring electric connection pads. The assembly is placed on the integrated control circuit, the growth substrate and the crystallites are removed, and trenches are formed in the stack so as to delimit a plurality of islets, each islet being configured to form a microLED.

Abstract: A method and a system for generating a time-frequency representation of an aperiodic continuous input signal comprising generating a periodic train of short pulses having a repetition frequency, and sampling the signal temporally using the periodic train of short pulses to obtain a temporally sampled signal, the temporally sampled signal comprising a plurality of sampled copies of the input signal, each sampled copy being spaced in function of the repetition frequency of the periodic train of short pulses. The temporally sampled signal is delayed based on the repetition frequency to obtain a delayed temporally sampled signal comprising a plurality of delayed sampled copies, a spectral representation of a given delayed sampled copy being delayed in function of the repetition frequency. The delayed temporally sampled signal is evaluated over consecutive time slots to obtain, for each consecutive time slot, a respective output signal in the time-frequency domain.

Abstract: The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4+ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR??+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR??+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.

Abstract: The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.

Abstract: Electrically conductive nanocomposite particles including a core of a C1-C6 alkyl polyacrylate homopolymer or a copolymer of C1-C6 alkyl acrylate and of an ?,?-unsaturated amide comonomer, a shell of polyaniline, and a non-ionic surfactant, for printing on a stretchable substrate. Also, a printed stretchable substrate obtained from the electrically conductive nanocomposite particles, which is usable, for example, in the field of printed electronics or connected clothing.

Abstract: A method for transfer of heat between a first and a second fluid, wherein the first and the second fluid circulate respectively on both sides of a thermally conductive wall of a monobloc assembly formed in a single piece. The monobloc assembly, which is arranged in the interior of a device, includes: a first, three-dimensional, cellular, thermally conductive structure through which the first fluid can pass; at least the thermally conductive wall; and a second, three-dimensional, cellular, thermally conductive structure through which the second fluid can pass. The first and second three-dimensional, cellular structures are situated on both sides of and integral with the wall such that heat transfer is carried out from the first to the second fluid through the wall, and both first and second fluids are under liquid phases and under gaseous phases, with the liquid phases circulating in a direction opposite that of the gaseous phases.

Abstract: A method of prognosis of patient outcome and of the resistance to a chemotherapy treatment of an individual afflicted by a tumor. The method involves determining the amount of the product of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO: 1 to SEQ ID NO: 160.

Abstract: A quantum device including: several spin qubits arranged as a matrix and each comprising a quantum dot; several electrometers each electrostatically coupled to a potential well of one of the quantum dots; circuits for applying an excitation signal to an input electrode of each electrometer, configured such that a value of the frequency, phase or maximum amplitude of each excitation signal is different from that of the other excitation signals, and applying a same excitation signal on electrometers coupled to a same row od qubits; a transimpedance amplifier having an input coupled to output electrodes of the electrometers; a demultiplexing circuit including an input electrically coupled to an output of the transimpedance amplifier, and configured to demultiplex the output signals to be delivered by the electrometers.

Abstract: The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.

Abstract: Disclosed is a system for generating a spatially localized, high-intensity laser beam, including: a laser source designed to generate a burst of N laser pulses with a duration of less than or equal to one picosecond, the N laser pulses having a first repetition frequency greater than or equal to 0.5 gigahertz; a resonant optical cavity designed to receive and store the burst of N laser pulses, the resonant optical cavity being designed to focus the burst of N laser pulses in an interaction region of the resonant optical cavity; and a servo control system designed to control the first repetition frequency relative to the roundtrip distance in the resonant optical cavity, such that the N pulses of the burst are superimposed temporally and spatially by constructive interferences in the interaction region so as to form one giant ultra-short and high-energy pulse.

Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Abstract: Described herein are methods, compositions and processes related to a microbial-based biosensor system for the detection of small molecules and analytes based on an analyte-responsive transcription factor-DNA binding mechanism with either a ratiometric fluorescent output through Förster resonance energy transfer (FRET) or a redox sensor output for the quantification of the target analyte with high sensitivity.

Abstract: Disclosed are a method for preparing a hydroalcoholic extract obtained from a biomass of the shoots of a plant from the family of Plumbaginaceae, a butanol extract of Armenia maritima, a method for the preparation thereof, the use thereof, and compositions containing same.

Abstract: An MRI method is disclosed for the geometrical characterisation of pulmonary airways on the basis of a first tridimensional image of at least one bronchus of a bronchial tree and includes: acquiring a first MRI image, an MRI sequence being synchronised with a respiratory frequency; filtering the first image; segmenting a portion of the filtered image including the contours of the bronchial tree and its inner volumetric portion; estimating at least one plane of cut of a bronchus; generating at least one image slice of a bronchus; estimating, for each image slice, an area contained within the bronchial wall and/or a bronchial wall thickness.

Abstract: The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.